A factory run by pharmaceutical group GSK in Saint-Amand-les-Eaux is engaged in a race against time in the fight against Covid-19. It manufactures the adjuvant intended to reinforce the effectiveness of some of the future vaccines. GSK has set itself the goal of producing up to a billion doses of this adjuvant in 2021, several hundred million of which are expected to come out of this northern plant. The remaining doses are produced at GSK sites in Belgium and the United States.